Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Argos Therapeutics

- PMLiVE

Roche’s fixed-duration lymphoma treatment approved by European Commission

Approximately 36,000 people are diagnosed with DLBCL each year in Europe

- PMLiVE

BeiGene signs $1.3bn deal with DualityBio for investigational solid tumour ADC

Antibody-drug conjugates are designed to target tumour cells while sparing healthy cells

- PMLiVE

Takeda and F-star announce immunotherapy partnership worth over $1bn

Both companies will research and develop antibodies for new immuno-oncology targets

- PMLiVE

[Free Case Study Booklet] Accelerating Patient Recruitment in a global rare disease trial

See how Innovative Trials supported a Top 5 pharma to complete enrollment in a Phase 2 Lupus study

Innovative Trials

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 lung cancer study

The investigational drug met the dual primary endpoint of progression-free survival

Katherine Tupper and Holly Joscelyne's top takeaways from the Patients as Partners conference 2023

Patients as Partners – putting people first in clinical trials

Cuttsy+Cuttsy's key takeaways from the Patients as Partners conference 2023

Cuttsy + Cuttsy

Pride Month 2023 – Innovative Trials

Innnovative Trials' Equality & Diversity committee celebrates Pride Month

Innovative Trials

- PMLiVE

Pfizer’s Litfulo approved by FDA as first treatment for adolescents with severe alopecia areata

Almost 20% of patients with the autoimmune disease are diagnosed before the age of 18

- PMLiVE

Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

The approval for the leukaemia drug was supported by additional data from two phase 3 studies

[Free Whitepaper] 5 Principles for Greater Diversity in Patient Recruitment

Discover how community engagement could enhance diversity in clinical trials patient recruitment

Innovative Trials

- PMLiVE

Innovative Trials attended the Inspire Hertfordshire Award gala dinner

Innovative Trials, a global clinical trial patient recruitment and retention company based in Hertfordshire, has been recognised for its contribution to the county’s economy and business reputation.

Innovative Trials

- PMLiVE

Pfizer’s Talzenna combination receives FDA approval for metastatic prostate cancer

Up to 20% of patients develop metastatic prostate cancer within five to seven years of diagnosis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links